March 25 (Reuters) - Oryzon Genomics SA ORY.MC:
STRENGTHENS VAFIDEMSTAT PATENT PORTFOLIO WITH U.S. NOTICE OF ALLOWANCE
U.S. PATENT EXPECTED TO REMAIN IN FORCE UNTIL AT LEAST 2040, EXCLUDING ANY POTENTIAL PATENT TERM ADJUSTMENTS OR EXTENSIONS
PATENT PORTFOLIO COVERS THE USE OF VAFIDEMSTAT FOR TREATING NON-AGGRESSIVE SYMPTOMS OF BORDERLINE PERSONALITY DISORDER
Source text